[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"major-adverse-cardiovascular-events-mace\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:major-adverse-cardiovascular-events-mace":100},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,74],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100642637",false,"NCT07634666","Prediction of Myocardial Injury After Non-Cardiac Surgery in Urologic Cancer Patients","Prediction of Myocardial Injury After Major Non-Cardiac Surgery in Patients With Urologic Cancer: A Prospective Multicenter Observational Study","URO-MINS","Inclusion Criteria:\n\n* Age ≥ 60 years\n* Patients scheduled for major non-cardiac surgery under general anesthesia due to urologic cancer (e.g., radical prostatectomy, radical nephrectomy, partial nephrectomy)\n* Patients who undergo preoperative standard 12-lead electrocardiography\n* Patients classified as having intermediate or higher surgical risk\n* Patients who can be followed for at least 30 days postoperatively\n* Patients who voluntarily provide written informed consent to participate in this study\n\nExclusion Criteria:\n\n* History of major adverse cardiovascular events (MACE) within 6 months prior to surgery\n* Inability to obtain essential clinical information required for study participation and follow-up\n* Patients who are not hospitalized after surgery\n* Individuals deemed inappropriate for participation in the study by the investigator due to legal or psychiatric reasons","ALL","60 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","This prospective multicenter observational study aims to evaluate the predictive value of artificial intelligence-based analysis of preoperative 12-lead electrocardiography for myocardial injury after non-cardiac surgery (MINS) and major adverse cardiovascular events (MACE) within 30 days after surgery in patients undergoing non-cardiac surgery for urologic cancer.",[24,25,26],"Myocardial Injury After Non-cardiac Surgery","Urologic Cancer","Major Adverse Cardiovascular Events (MACE)",[28,29,24,30,31,25],"Artificial Intelligence","Electrocardiography","Major Adverse Cardiovascular Events","Perioperative Cardiovascular Risk","NOT_YET_RECRUITING","2026-06-11",{"date":35,"type":36},"2026-06-15","ACTUAL",{"date":38,"type":20},"2026-06-01",{"date":40,"type":20},"2028-12-31",{"name":42,"class":43},"Korea University Anam Hospital","OTHER",{"id":45,"slug":4,"hasResults":10,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":10,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100580876","NCT06843005","Serial Coronary CTA-based Plaque Progression Detection for Management of Coronary Heart Disease","Serial Coronary CTA-based Plaque Progression Detection for Management of Coronary Heart Disease: a Randomised Controlled Trial","SUCCESS","Inclusion Criteria:\n\n1. Age between 18 and 80 years old;\n2. Known patients with non-obstructive coronary artery disease (disease duration ≥2 years);\n3. Patients who agree to undergo follow-up CCTA examinations and cooperate in completing follow-up observations.\n\nExclusion Criteria:\n\n1. Patients who have experienced ACS or PCI\u002FCABG;\n2. Patients who have experienced adverse cardiovascular and cerebrovascular events;\n3. Patients who have undergone follow-up CCTA or DSA examinations before enrollment;\n4. Patients with severe hepatic and renal dysfunction;\n5. Patients with contraindications to CCTA examinations;\n6. Patients with poor initial CCTA image quality or data loss.","18 Years","80 Years",{"count":54,"type":20},3100,"INTERVENTIONAL",[57],"NA","The primary objective of this study is to evaluate whether a management strategy based on coronary computed tomography angiography (CCTA) for patients with non-obstructive coronary artery disease can improve the LDL-C target achievement rate compared to a traditional management strategy without follow-up CCTA, thereby reducing the incidence of major adverse cardiovascular and cerebrovascular events over a 3 years period, including all-cause mortality, myocardial infarction, ischemia driven revascularation and stroke.",[26,60,61,62],"Prevention","Coronary Artery Disease(CAD)","CT Angiography","RECRUITING","2026-03-19",{"date":66,"type":36},"2026-03-24",{"date":68,"type":36},"2025-02-28",{"date":70,"type":20},"2028-12-30",{"name":72,"class":43},"Zhang longjiang,MD",1,{"id":75,"slug":4,"hasResults":10,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":10,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":81,"targetDuration":4,"studyType":55,"phases":83,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100619723","NCT07348328","Vitamin B Supplementation for Patients Undergoing Cardiovascular Surgery","Vitamin B Supplementation for Patients Undergoing Cardiovascular Surgery: A Randomized Controlled Trial","PANDA XII","Inclusion Criteria:\n\n* Aged 18-80 years, regardless of gender;\n* Scheduled to receive cardiovascular surgery at the research center, including coronary artery bypass grafting (CABG), cardiac valve replacement\u002Frepair, and great vessel surgery;\n* Preoperative assessment indicates that the patient is expected to complete the 6-month postoperative follow-up;\n* The patient or their authorized agent signs a written informed consent form.\n\nExclusion Criteria:\n\n* Regular supplementation with Compound Vitamin B (daily dose ≥ 1.5 times the recommended dietary allowance) or separate supplementation with folic acid, vitamin B6, or B12 within 3 months before surgery;\n* Severe hepatic or renal insufficiency (liver function: ALT\u002FAST \\> 3 times the upper limit of normal, or total bilirubin \\> 2 times the upper limit of normal; renal function: serum creatinine \\> 265 μmol\u002FL, or requiring long-term dialysis treatment);\n* Malignant tumors, severe hematological diseases (e.g., megaloblastic anemia, aplastic anemia), severe malnutrition (albumin \\\u003C 25 g\u002FL);\n* History of allergy to Compound Vitamin B preparations or placebo components; Pregnant women, lactating women, or those planning to become pregnant during the study period;\n* Currently participating in other interventional clinical trials;\n* Moderate to severe cognitive impairment without a fixed caregiver, unable to cooperate with treatment and follow-up;\n* Preoperatively diagnosed with severe infection, septicemia, or septic shock.",{"count":82,"type":20},1000,[57],"This study is a multicenter, randomized controlled, double-blind, placebo-controlled parallel trial designed to evaluate the effect of perioperative supplementation with Compound Vitamin B on patients undergoing cardiovascular surgery. A total of 1,000 patients aged 18-80 years who are scheduled to receive cardiovascular surgeries such as coronary artery bypass grafting (CABG) and valve replacement will be enrolled. They will be randomly assigned at a 1:1 ratio to either the experimental group (perioperative supplementation with Compound Vitamin B tablets, once daily from 3 days before surgery to 6 months after surgery) or the control group (oral placebo), with both groups receiving standardized perioperative treatment.",[86,26],"Cardiovascular Surgical Procedures",[88,89,30],"Compound Vitamin B","Cardiovascular Surgery","2026-01-09",{"date":92,"type":36},"2026-01-16",{"date":94,"type":20},"2026-02-01",{"date":96,"type":20},"2027-12-31",{"name":98,"class":43},"Nanjing Medical University",2,""]